Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Hematology

Navigating Your Amyloidosis Diagnosis

At a Glance

Amyloidosis is a rare condition caused by misfolded proteins building up in organs like the heart and kidneys. Identifying whether you have AL or ATTR amyloidosis is crucial, as each requires a different specialist and modern treatments can effectively slow disease progression.

Receiving a diagnosis of amyloidosis often comes at the end of a long and exhausting search for answers. Many patients spend months or even years visiting different specialists before the pieces finally fit together [1][2]. While the news can be overwhelming, having a definitive diagnosis is the first step toward a targeted treatment plan.

What Is Amyloidosis?

At its simplest, amyloidosis is a condition caused by “misfolded” proteins [3]. Proteins are the building blocks of the body, and they must be folded into specific shapes to work correctly. In amyloidosis, certain proteins lose their shape and become “sticky,” clumping together to form amyloid fibrils (abnormal protein deposits) [4][5]. These deposits can build up in organs like the heart, kidneys, and liver, interfering with their ability to function [1][6].

Validating Your Journey: The “Diagnostic Odyssey”

If you feel frustrated or anxious, it is for a good reason. Because amyloidosis is rare and its symptoms (like fatigue or shortness of breath) mimic more common conditions like heart failure, the “diagnostic odyssey” is often long [1][7].

  • AL Amyloidosis: Patients often wait 8 to 11 months for a diagnosis [8].
  • ATTR Amyloidosis: The wait can be much longer, ranging from 10 months to several years [1][2].
  • The Emotional Toll: It is common to feel a mix of relief (finally knowing what is wrong) and significant anxiety or depression [1][9].

Understanding the Two Main Types

Not all amyloidosis is the same. It is critical to know your specific subtype because the treatments are completely different [10][11].

Type What Causes It? Who Typically Treats It?
AL (Light Chain) Abnormal plasma cells in the bone marrow produce “light chain” proteins [5]. Hematologists/Oncologists (using treatments similar to those for blood cancers) [12].
ATTR (Transthyretin) A protein called TTR, made in the liver, becomes unstable [13]. Cardiologists and Neurologists [14].

Important Distinction: AL amyloidosis is a plasma cell disorder closely related to blood cancers like multiple myeloma [5]. Because it is driven by abnormal cells in your bone marrow, it is treated by oncologists using chemotherapy and targeted cancer drugs [15]. ATTR amyloidosis, on the other hand, is not a cancer. It can be “wild-type” (occurring naturally with age) or “hereditary” (caused by a genetic mutation passed through families) [13][16].

Three Stabilizing Facts for Your Future

The landscape of amyloidosis management has changed more in the last few years than in the previous several decades combined [3][17].

  1. Revolutionary New Drugs: For AL amyloidosis, the addition of monoclonal antibodies (like daratumumab) has dramatically improved how well patients respond to treatment [18][19]. For ATTR, new “stabilizers” and “silencers” (like tafamidis or RNAi therapies) can now slow or even halt disease progression [13][20].
  2. Non-Invasive Diagnosis: In the past, a painful heart biopsy was often required. Today, doctors can often diagnose ATTR amyloidosis using specialized heart scans called bone scintigraphy [21][22].
  3. Specialized Care Teams: Experts now emphasize a multidisciplinary approach, meaning you may have a team of specialists working together to manage both the underlying protein problem and the symptoms in your organs [4][14].

Amyloidosis is a serious condition, but it is no longer the “untreatable” disease it was once considered. Modern medicine is now focused on helping you manage the condition and maintain your quality of life [23][9].

Common questions in this guide

What is the difference between AL and ATTR amyloidosis?
AL amyloidosis is caused by abnormal plasma cells in the bone marrow and is closely related to blood cancers. ATTR amyloidosis is caused by an unstable protein made in the liver and can occur naturally with age or be inherited through genetics.
Is amyloidosis a type of cancer?
ATTR amyloidosis is not a cancer, though it is a serious condition. AL amyloidosis, on the other hand, is a plasma cell disorder closely related to blood cancers like multiple myeloma and is treated by hematologists and oncologists.
Why does it take so long to get diagnosed with amyloidosis?
Amyloidosis is rare, and its early symptoms like fatigue or shortness of breath closely mimic much more common conditions like heart failure. This often leads to a long 'diagnostic odyssey' involving multiple specialists before the correct diagnosis is made.
Do I need a heart biopsy to be diagnosed with amyloidosis?
Historically, a painful heart biopsy was required for diagnosis. Today, doctors can often diagnose ATTR amyloidosis non-invasively using specialized imaging tests called bone scintigraphy heart scans.
What treatments are available for amyloidosis?
Treatment is highly targeted to your specific subtype. AL amyloidosis is treated with chemotherapy and monoclonal antibodies to target bone marrow cells. ATTR amyloidosis is treated with stabilizers or RNAi therapies that slow or stop the unstable liver proteins.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific type of amyloidosis do I have (AL, ATTR, or another type), and how was that confirmed?
  2. 2.What is my current 'organ stage,' and which organs (heart, kidneys, nerves) are currently affected?
  3. 3.Is my amyloidosis the 'wild-type' (age-related) or 'hereditary' (genetic) version, and do my family members need testing?
  4. 4.How will we measure my response to treatment? Are there specific blood markers or imaging tests we will use regularly?
  5. 5.Are there any clinical trials available that might be a good fit for my specific subtype?
  6. 6.Which specialists will be on my care team, and how will they coordinate with one another?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Amyloidosis from the patient perspective: the French daily impact of amyloidosis study.

    Damy T, Adams D, Bridoux F, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(3)):165-174 doi:10.1080/13506129.2022.2035354.

    PMID: 35144512
  2. 2

    Gateway and journey of patients with cardiac amyloidosis.

    Dang D, Fournier P, Cariou E, et al.

    ESC heart failure 2020; (7(5)):2418-2430 doi:10.1002/ehf2.12793.

    PMID: 32588554
  3. 3

    Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis.

    Kim D, Choi JO, Kim K, et al.

    International journal of heart failure 2020; (2(4)):231-239 doi:10.36628/ijhf.2020.0016.

    PMID: 36262171
  4. 4

    Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.

    Hester LL, Gifkins DM, M Bellew K, et al.

    European journal of haematology 2021; (107(4)):428-435 doi:10.1111/ejh.13679.

    PMID: 34137077
  5. 5

    Primary systemic amyloidosis: A brief overview.

    Hughes MS, Lentzsch S

    Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

    PMID: 39672504
  6. 6

    Associations of Patients with Pericardial Effusion Secondary to Light-Chain or Transthyretin Amyloidosis- A Systematic Review.

    Javed N, Singh K, Shirah J, Vittorio TJ

    Current cardiology reviews 2024; (20(4)):e080324227805 doi:10.2174/011573403X280737240221060630.

    PMID: 38465427
  7. 7

    Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

    Bistola V, Parissis J, Foukarakis E, et al.

    Heart failure reviews 2021; (26(4)):861-879 doi:10.1007/s10741-020-10062-w.

    PMID: 33452596
  8. 8

    History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.

    Kharoubi M, Bézard M, Galat A, et al.

    ESC heart failure 2021; (8(6)):5501-5512 doi:10.1002/ehf2.13652.

    PMID: 34714605
  9. 9

    Supportive Care for Patients with Systemic Light Chain Amyloidosis.

    Wong SW, Fogaren T

    Hematology/oncology clinics of North America 2020; (34(6)):1177-1191 doi:10.1016/j.hoc.2020.08.007.

    PMID: 33099432
  10. 10

    99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.

    Quarta CC, Zheng J, Hutt D, et al.

    European heart journal. Cardiovascular Imaging 2021; (22(11)):1304-1311 doi:10.1093/ehjci/jeab095.

    PMID: 34254119
  11. 11

    Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment.

    Patel RK, Fontana M, Ruberg FL

    Circulation. Cardiovascular imaging 2021; (14(6)):e009025 doi:10.1161/CIRCIMAGING.121.009025.

    PMID: 34129344
  12. 12

    AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

    Bianchi G, Zhang Y, Comenzo RL

    JACC. CardioOncology 2021; (3(4)):467-487 doi:10.1016/j.jaccao.2021.09.003.

    PMID: 34729520
  13. 13

    Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story.

    Burton A, Castaño A, Bruno M, et al.

    Drug design, development and therapy 2021; (15()):1225-1243 doi:10.2147/DDDT.S289772.

    PMID: 33776421
  14. 14

    Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study.

    Jaccard A, Bridoux F, Roeloffzen W, et al.

    Clinical lymphoma, myeloma & leukemia 2024; (24(5)):e205-e216 doi:10.1016/j.clml.2024.01.013.

    PMID: 38453615
  15. 15

    Supportive Care in AL Amyloidosis.

    Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

    Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

    PMID: 32235118
  16. 16

    Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.

    Streicher N, Amass L, Wang R, et al.

    Cardiology and therapy 2024; (13(2)):359-368 doi:10.1007/s40119-024-00362-9.

    PMID: 38521883
  17. 17

    Amyloid Cardiopathy and Aortic Stenosis.

    Gherasim L

    Maedica 2021; (16(3)):473-481 doi:10.26574/maedica.2020.16.3.473.

    PMID: 34925605
  18. 18

    Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

    Kastritis E, Palladini G, Minnema MC, et al.

    The New England journal of medicine 2021; (385(1)):46-58 doi:10.1056/NEJMoa2028631.

    PMID: 34192431
  19. 19

    Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

    Palladini G, Milani P, Malavasi F, Merlini G

    Cells 2021; (10(3)) doi:10.3390/cells10030545.

    PMID: 33806310
  20. 20

    Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis.

    Grogan M, Sheikh FH, Sperry BW, et al.

    Molecular therapy. Nucleic acids 2025; (36(3)):102590 doi:10.1016/j.omtn.2025.102590.

    PMID: 40686854
  21. 21

    Multidisciplinary Approaches for Transthyretin Amyloidosis.

    Koike H, Okumura T, Murohara T, Katsuno M

    Cardiology and therapy 2021; (10(2)):289-311 doi:10.1007/s40119-021-00222-w.

    PMID: 34089151
  22. 22

    Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

    Gillmore JD, Maurer MS, Falk RH, et al.

    Circulation 2016; (133(24)):2404-12 doi:10.1161/CIRCULATIONAHA.116.021612.

    PMID: 27143678
  23. 23

    Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.

    Nativi-Nicolau JN, Karam C, Khella S, Maurer MS

    Heart failure reviews 2022; (27(3)):785-793 doi:10.1007/s10741-021-10080-2.

    PMID: 33609196

This page is for informational purposes only and does not replace professional medical advice. Always consult your multidisciplinary healthcare team to understand the specifics of your amyloidosis diagnosis and treatment plan.

Get notified when new evidence is published on Amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.